Acute Respiratory Distress Syndrome (ARDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy and TPP Insights

Thelansis’s “Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung injury characterised by rapid-onset bilateral pulmonary infiltrates, refractory hypoxaemia, and reduced lung compliance — resulting from diffuse alveolar damage, disruption of the alveolar-capillary barrier, and protein-rich oedema flooding — triggered by diverse direct pulmonary insults including pneumonia, aspiration, and inhalational injury, or indirect systemic insults including sepsis, pancreatitis, and major trauma. The Berlin Definition classifies ARDS by PaO2/FiO2 ratio into mild, moderate, and severe categories, guiding prognostic stratification and ventilatory management intensity. Dysregulated neutrophilic inflammation, cytokine-mediated endothelial injury, and impaired surfactant function perpetuate alveolar collapse and consolidation. Diagnosis is clinical — bilateral chest infiltrates on imaging, absence of cardiogenic pulmonary oedema, and hypoxaemia thresholds — with echocardiography and BNP excluding hydrostatic aetiology. Lung-protective mechanical ventilation — low tidal volume strategy targeting 6ml/kg predicted body weight, plateau pressure limitation, and individualised PEEP titration — remains the cornerstone intervention demonstrably reducing mortality. Prone positioning for moderate-severe ARDS significantly improves oxygenation and survival. Neuromuscular blockade, conservative fluid strategy, and corticosteroids in selected patients provide additional benefit. No pharmacological disease-modifying therapy is established beyond supportive care. Prognosis carries significant mortality, particularly in severe disease; ICU-based multidisciplinary management, early rehabilitation, and patient-centred post-ICU psychological support are indispensable to optimising survival and long-term functional recovery.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Acute Respiratory Distress Syndrome (ARDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026